共 47 条
- [21] Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024 [J]. EUROPEAN UROLOGY, 2021, 79 (03) : E83 - E84
- [22] Reply to Mauricio Plata, Cesar Diaz Ritter, and Nicolas Badillo's Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.009 [J]. EUROPEAN UROLOGY, 2023, 84 (01) : E26 - E27
- [23] Reply to Kamal Kant Sahu's Letter to the Editor re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.012 [J]. EUROPEAN UROLOGY, 2022, 81 (06) : E147 - E148
- [24] Re: Christopher JD Wallis, Zachary Klaassen, Bimal Bhindi, et al. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.10.002 [J]. EUROPEAN UROLOGY, 2018, 73 (03) : E49 - E50
- [25] Re: Andreas Hiester, Yue Che, Achim Lusch, et al. Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.10.021 [J]. EUROPEAN UROLOGY, 2023, 83 (06)
- [26] Re: Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.05.031 [J]. EUROPEAN UROLOGY, 2022, 82 (05) : E148 - E148
- [27] Reply to Sungeun Kim, Jae Il Shin, and Jonathan Evan Shoag's Letter to the Editor re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j. eururo.2020.11.010 [J]. EUROPEAN UROLOGY, 2021, 80 (01) : E15 - E16
- [28] Reply to Benjamin Davies, Keith Kowalczyk RE: Zachary Klaassen, Emily Vertosick, Andrew J. Vickers, et al. Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.01.041 [J]. EUROPEAN UROLOGY, 2022, 82 (01) : E12 - E12
- [29] Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033 [J]. EUROPEAN UROLOGY, 2017, 71 (02) : E55 - E55
- [30] Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033 [J]. EUROPEAN UROLOGY, 2017, 71 (01) : E9 - E10